Reports
Global Cell and Gene Therapy Market Size, Growth, Trends: By Therapeutic Class: Rare Diseases, Oncology, Haematology, Cardiology, Ophthalmology, Neurology; By Type: Cell Therapy Types, Others; By Product Type; By End User; Regional Analysis; Current Scenario Evaluation; Challenges and Unmet Needs; Supplier Landscape; 2023-2031
Cell and Gene Therapy Market Outlook
In 2021, the cell and gene therapy market size was estimated to be worth USD 5.34 billion. The market is expected to rise at a CAGR of 19.02% in the forecast period of 2023-2031 and by 2030, the market value is anticipated to be worth USD 21.5 billion.
Company News
In July 2022, the National Institute for Innovation in Manufacturing Biopharmaceuticals and the Alliance for Regenerative Medicine released the standard practices and methodologies for cell and gene therapy field assistance. This will also help the scientists to overcome the manufacturing challenges.
In July 2022, a company called Discovery Life Sciences announced its acquisition of AllCells to create a combined business, “AllCells, a Discovery Life Sciences Company”.
Cell and Gene Therapy: A Brighter Future Outlook
The cell and gene therapy market is a comparatively new integration of technology and genomics, that has been enthralled by substantial new developments in the healthcare industry. Cell and gene therapy are the two conjoining therapies incorporated as a single therapy for efficient and effective treatment. The emerging new cell and gene therapies are sure to burgeon the biotechnological and biopharmaceutical industry in the coming years.
Cell therapy works on the principle of alteration, implantation, or restoration of cells or by extrapolating cells to carry the treatment through the body. In cell therapy, cells are modified outside the body, that is, in ex vivo conditions and then injected into the patient.
On the other hand, gene therapy works by incorporating, deactivating, or displacing the genes into cells which can occur both inside (in vivo) and outside (ex vivo) of the body.
Effective Remedies
In the healthcare sector, some of the major treatments and curative remedies are developed using cell and gene modifications. Cell and gene therapy works by modifying the genes in particular cells and injecting them into the body. The essential resemblance between cell and gene therapy is the ability to mitigate the underlying cause of genetic disorders. There are enormous cell and gene therapies based on the origin or destination as per the treatment requirements.
Based on the genetic manipulation and source, cell and gene therapies are classified into two categories- ex vivo and in vivo. The ex vivo ones are further categorised into allogenic and autologous.
Autologous therapies require raw materials to be referenced and returned to the same subject. At the same time, allogeneic therapies deliver it through material from any optimum donor. Cell therapies utilise genetically modified (for example CAR-T therapy) and non-genetically modified cells (Beta cells T1D) as medicines. In contrast, gene therapies use viral (lipid/polymer based) and non-viral (mRNA) vectors as medicines.
Researchers are working on several new cell and gene therapies in the new disease sectors, which will help in improving the overall market outlook.
According to the cell and gene therapy market research report, the market can be categorised into the following segments:
Market Breakup by Therapeutic Class
- Rare Diseases
- Oncology
- Haematology
- Cardiology
- Ophthalmology
- Neurology
- Others
Market Breakup by Therapy Type
- Cell Therapy Types
- Autologous Cell Therapy
- Autogenic Cell Therapy
- Ex vivo Cell Therapy
- In vivo Cell Therapy
- Gene Therapy Types
- Somatic Cell Gene Therapy
- Germline Gene Therapy
- Ex vivo Gene Therapy
- In vivo Gene Therapy
Market Breakup by Product Type
- Yescarta
- Provenge
- Luxtura
- Kymriah
- Imlygic
- Gintuit
- MACI
- Laviv
- Gendicine
- Oncorine
- Neovasculgen
- Strimvelis
- Invossa
- Zolgenesma
- Tecartus
- Lisocel
- Zyntelego
- Others
Market Breakup by Route of End User
- Hospitals
- Ambulatory Surgical Centres
- Wound Care Centres
- Cancer Care Centres
- Others
Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Cell and Gene Therapy Market Scenario
The emerging cell and gene therapies seem promising in commercial aspects. Key market leaders will be the gene therapy companies that will provide fast and effective treatment for debilitating diseases.
Gene therapies developed by small, medium, and big biotech and pharmaceutical companies also tend to attract the attention of investors. According to Food and Drug Administration’s anticipation, by 2025, 10 to 20 new cell and gene therapies can be approved.
According to the research surveys, publicly traded cell and gene therapies also witnessed a 70% increase in stocks compared to the previous year. This demonstrates the substantial growth of the cell and gene therapy market in the upcoming years.
Rising Prevalence of Chronic Diseases, Rising Support from the Government, and Technological Advancements are Driving the Market Growth
The increase in the prevalence of chronic disorders, like cancer, is responsible for driving the growth of this market. The increased expenditure in the R&D sector and enhanced government support are also expected to boost the cell and gene therapy market development during the forecast period.
Advanced technologies and better healthcare infrastructure facilities are the additional factors helping in the development of this market.
North America Accounts for the Largest Market Share
North America accounts for a significant share of the global market due to the growth of the market in the United States. The United States of America has witnessed a substantial increase in biopharmaceutical companies performing clinical trials in cell and gene therapy. Thus, the United States hold a significant share in the global cell and gene therapy market.
The growth of the market in the United States can be attributed to the higher presence of the key players in the region. It was found that more than 1000 companies worldwide are working on cell and gene therapy, out of which more than 500 companies are based in the United States.
Across the globe, around 250 are from Europe, about 150 are in the Asian region and the rest are found in other regions like Oceania, New Zealand, Australia, and Africa.
Therapeutic Landscape
Over the last decade, cell and gene therapy have accelerated and resulted in multiple effective treatments for various indications. These novel therapies and strategies have grabbed the attention of the entire biotech and pharma industry and are visible as future hallmarks of the global cell and gene therapy market. The field of cell and gene therapy is still young compared to other modalities.
A collaborative industry effort has focused on applying chimeric anti-receptor T-cells for oncology indications. The incorporation of cell and gene therapy in hematopoietic stem cells has paved the pathway for new therapeutic strategies, including haematological, neurological, and ocular symptoms.
Rising Focus on Various Niche Technologies like CRISPR, Xenotransplantation, Stem Cell Technology are Aiding the Market Growth
CRISPR-Cas-9 gene editing works on the principle of cell and gene editing, which is brought into the market to treat several genetic forms of vision loss that conventional therapies cannot treat.
Xenotransplantation, an organ transplantation technique based on cell and gene editing application, makes it possible to do the needful organ transplant in the best way possible with comparable ease and precision. In this technique, animal organs are harvested and placed into human patients. This will help the patients to get rid of the prolonged waiting time and thus decreasing the risks of mortalities.
The eye has been the leading centre for emerging cell and gene therapies. Incorporating stem cells from the retina can give rise to photoreceptors (light-sensitive cells) required for vision. Researchers are also developing cell and gene editing methodologies to help treat incurable eye disorders.
There is another novel therapy available in the market, which uses stem cells from one’s healthy eye to rectify or treat the other eye’s affected cornea, thus helping in vision rectification.
Treatment of glioblastoma can be done by incorporating microRNAs in emerging technology. Apart from this, microRNAs have also been beneficial through miR-10b blocking activity, leading to the death of tumour cells. These novel treatment strategies will help in the substantial growth of the cell and gene therapy market in the forecast period.
Several viral vectors have also proved functional in treating neurogenerative disorders. For example, a frequently used vehicle for cell and gene therapy, AAV viral vector, has been modified to enter the blood-brain barrier and treat the needful.
Scientists have also discovered an innovative cell replacement technique for treating gastrointestinal diseases. In this technique, the donor cells can be extracted from the patient’s gut or subcutaneous fat and then cultivated ex vivo to form the progenitors, giving rise to enteric neurons. These neurons pave the treatment pathway for the heart, brain, and spinal cord.
Novel regenerative approaches that work on the cell and gene editing principle have also been discovered. This technique helps restore the hair cells that are either damaged or lost, which aids in hearing. This is done by stimulating the ear’s existing cells to convert and birth to novel hair cells.
Cell and gene therapies are not only used for diagnostic or treatment purposes but also as effective modes of drug delivery systems. For example, microneedles which can easily access the legion of immune cells, are the critical targets of vaccination.
These therapies reawaken the inactive X-chromosome, which could help in the devastating, rare neurodevelopmental disorders, especially in females.
Tremendous efforts of scientists, researchers and healthcare professionals will lead to innovative cell and gene therapies, that will lay the foundation for next-generation technologies.
Henceforth, all these novel treatments will help in the improvement of healthcare and the global economy. These new treatment strategies will majorly drive the growth of the global cell and gene therapy market.
Clinical Trial Landscape
According to Alliance for regenerative medicine data, thousands of clinical trials are in progress by diverse healthcare organisations and pharma companies. Despite the numerous constraints and hindrances, some cell and gene therapies aim to provide effective treatment. Thus, to get a safer and more efficient treatment, researchers are modifying and reformulating the conventional therapies with the incorporation of cell and gene editing leading to the development of new targeted therapies.
More than 50% of cell and gene therapy trials are from oncology, followed by cardiovascular and musculoskeletal disorders.
Emerging Regenerative Medicine and Gene Alteration Technologies
Novartis Pharmaceuticals were doing clinical trials to monitor the long-term safety of CAR-T patients. The purpose of this trial was to monitor all patients who were incorporated with CAR-T therapies for fifteen years following their last CAR-T infusion.
Researchers did clinical trials for the first FDA-approved in vivo therapy to treat retinal dystrophies caused by the modified RPE65 gene. This therapy is incorporated with the help of the adeno-associated vector, which will target the retinal cells and insert the healthy genes into the patient’s eye.
Cell and gene therapy for Haemophilia is also entering the last stage of the clinical trials. There are already ten ongoing trials for Haemophilia A and six for Haemophilia B. In this therapy, a single injection of adeno-associated virus (AAV) is engineered in the liver to produce the essential clotting factor for the rest of the patient’s life.
Another set of clinical trials utilising cell and gene alteration is under process in the USA to treat degenerative retinal diseases. In this therapy, an intraocular injection pass on the genes encoding for MCO protein into the retinal cells. These trials are also in the phase II stage.
Implementing cell and gene technology in healthcare has already provided enormous benefits to human health. Researchers’ tremendous efforts have anticipated a rapid increase in the approvals for cell and gene therapies. A rapid rise in authorisations for gene therapies is also expected. Careful planning and research are done to overcome all the hurdles and hindrances and for the vast development.
Several ongoing clinical trials are emerging as a driving factor for cell and gene therapy market growth and development.
Competitive Landscape
The report gives an in-depth analysis of the key players involved in the cell and gene therapy market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
- Amgen Inc.
- Bluebird Bio, Inc.
- Castle Creek Pharmaceutical Holdings
- Kite Pharma, Inc.
- Novartis AG
- Orchard Therapeutics plc.
- Pfizer, Inc.
- Spark Therapeutics, Inc.
- Vericel Corporation
- Dendreon Pharmaceuticals LLC.
- Human Stem Cells Institute
- Kolon Tissuegene Inc.
- Organogenesis Holdings Inc.
- Renova Therapeutics
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2016-2022 |
| Forecast Period | 2023-2031 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Therapeutic Class |
|
| Breakup by Type |
|
| Breakup by Product Type |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.1.1 Research Objectives
1.1.2 Key Findings of the Report
1.2 Limitations of the Study and Scope for Future Research
2 Research Methodology
3 Executive Summary
4 Global Cell and Gene Therapy Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Model
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Global Cell and Gene Therapy Market
6.1 Market Overview
6.2 Global Cell and Gene Therapy Market Analysis
6.2.1 Market Overview
6.2.1.1 Global Historical Cell and Gene therapy Market Value (2016-2022)
6.2.1.2 Global Forecast Cell and Gene therapy Market Value (2023-2031)
6.2.2 Global Cell and Gene Therapy Market by Therapeutic Class
6.2.2.1 Market Overview
6.2.2.1.1 Rare Diseases
6.2.2.1.2 Oncology
6.2.2.1.3 Haematology
6.2.2.1.4 Cardiology
6.2.2.1.5 Ophthalmology
6.2.2.1.6 Neurology
6.2.2.1.7 Others
6.2.3 Global Cell and Gene Therapy Market by Type
6.2.3.1 Cell Therapy Types
6.2.3.1.1 Autologous Cell Therapy
6.2.3.1.2 Autogenic Cell Therapy
6.2.3.1.3 Ex-vivo Cell Therapy
6.2.3.1.4 In-vivo Cell Therapy
6.2.3.2 Gene Therapy Types
6.2.3.2.1 Somatic Cell Gene Therapy
6.2.3.2.2 Germline Gene Therapy
6.2.3.2.3 Ex-vivo Gene Therapy
6.2.3.2.4 In-vivo Gene Therapy
6.2.4 Global Cell and Gene Therapy Market by Product Type
6.2.4.1 Market Overview
6.2.4.1.1 Yescarta
6.2.4.1.2 Provenge
6.2.4.1.3 Luxtura
6.2.4.1.4 Kymriah
6.2.4.1.5 Imlygic
6.2.4.1.6 Gintuit
6.2.4.1.7 MACI
6.2.4.1.8 Laviv
6.2.4.1.9 Gendicine
6.2.4.1.10 Oncorine
6.2.4.1.11 Neovasculgen
6.2.4.1.12 Strimvelis
6.2.4.1.13 Invossa
6.2.4.1.14 Zolgenesma
6.2.4.1.15 Tecartus
6.2.4.1.16 Lisocel
6.2.4.1.17 Zyntelego
6.2.4.1.18 Others
6.2.5 Global Cell and Gene Therapy Market by End User
6.2.5.1 Market Overview
6.2.5.1.1 Hospitals
6.2.5.1.2 Ambulatory Surgical Centres
6.2.5.1.3 Wound Care Centres
6.2.5.1.4 Cancer Care Centres
6.2.5.1.5 Others
6.2.6 Global Cell and Gene Therapy Market by Region
6.2.6.1 Market Overview
6.2.6.1.1 North America
6.2.6.1.2 Europe
6.2.6.1.3 Asia Pacific
6.2.6.1.4 Middle East & Africa
6.2.6.1.5 Latin America
6.2.7 North America
6.2.7.1 Historical Trend (2016-2022)
6.2.7.2 Forecast Trend (2023-2031)
6.2.7.3 Break Up by Country
6.2.7.3.1 United States of America
6.2.7.3.2 Canada
6.2.8 Europe
6.2.8.1 Historical Trend (2016-2022)
6.2.8.2 Forecast Trend (2023-2031)
6.2.8.3 Break Up by Country
6.2.8.3.1 United Kingdom
6.2.8.3.2 Germany
6.2.8.3.3 France
6.2.8.3.4 Italy
6.2.8.3.5 Others
6.2.9 Asia Pacific
6.2.9.1 Historical Trend (2016-2022)
6.2.9.2 Forecast Trend (2023-2031)
6.2.9.3 Break Up by Country
6.2.9.3.1 China
6.2.9.3.2 Japan
6.2.9.3.3 India
6.2.9.3.4 ASEAN
6.2.9.3.5 Australia
6.2.9.3.6 Others
6.2.10 Latin America
6.2.10.1 Historical Trend (2016-2022)
6.2.10.2 Forecast Trend (2023-2031)
6.2.10.3 Break Up by Country
6.2.10.3.1 Brazil
6.2.10.3.2 Argentina
6.2.10.3.3 Mexico
6.2.10.3.4 Others
6.2.11 Middle East and Africa
6.2.11.1 Historical Trend (2016-2022)
6.2.11.2 Forecast Trend (2023-2031)
6.2.11.3 Break Up by Country
6.2.11.3.1 Saudi Arabia
6.2.11.3.2 United Arab Emirates
6.2.11.3.3 Nigeria
6.2.11.3.4 South Africa
6.2.11.3.5 Others
7 Current Scenario Evaluation
7.1 Emerging Therapies & Clinical trials Synopsis
7.2 Patent Landscape and Impact
7.3 Cost of Treatment
7.4 Others
8 Challenges & Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop- out Analysis
8.3 Awareness and Prevention Gaps
9 Global Cell and Gene Therapy Industry Dynamics
9.1 Industry Drivers and Constraints
9.2 SWOT Analysis
9.3 Porter’s Five Forces
9.4 Key Demand Indicators
9.5 Key Price Indicators
9.6 Industry Events, Initiatives & Trends
9.7 Value Chain
10 Supplier Landscape
10.1 Amgen, Inc.
10.1.1 Company Overview
10.1.2 Product Portfolio
10.1.3 Demographic Reach and Achievements
10.1.4 Mergers and Acquisitions
10.1.5 Certifications
10.2 Bluebird Bio, Inc.
10.2.1 Company Overview
10.2.2 Product Portfolio
10.2.3 Demographic Reach and Achievements
10.2.4 Mergers and Acquisitions
10.2.5 Certifications
10.3 Castle Creek Pharmaceutical Holdings
10.3.1 Company Overview
10.3.2 Product Portfolio
10.3.3 Demographic Reach and Achievements
10.3.4 Mergers and Acquisitions
10.3.5 Certifications
10.4 Kite Pharma, Inc.
10.4.1 Company Overview
10.4.2 Product Portfolio
10.4.3 Demographic Reach and Achievements
10.4.4 Mergers and Acquisitions
10.4.5 Certifications
10.5 Novartis AG
10.5.1 Company Overview
10.5.2 Product Portfolio
10.5.3 Demographic Reach and Achievements
10.5.4 Mergers and Acquisitions
10.5.5 Certifications
10.6 Orchard Therapeutics plc.
10.6.1 Company Overview
10.6.2 Product Portfolio
10.6.3 Demographic Reach and Achievements
10.6.4 Mergers and Acquisitions
10.6.5 Certifications
10.7 Pfizer, Inc.
10.7.1 Company Overview
10.7.2 Product Portfolio
10.7.3 Demographic Reach and Achievements
10.7.4 Mergers and Acquisitions
10.7.5 Certifications
10.8 Spark Therapeutics, Inc.
10.8.1 Company Overview
10.8.2 Product Portfolio
10.8.3 Demographic Reach and Achievements
10.8.4 Mergers and Acquisitions
10.8.5 Certifications
10.9 Vericel Corporation
10.9.1 Company Overview
10.9.2 Product Portfolio
10.9.3 Demographic Reach and Achievements
10.9.4 Mergers and Acquisitions
10.9.5 Certifications
10.10 Dendreon Pharmaceuticals LLC.
10.10.1 Company Overview
10.10.2 Product Portfolio
10.10.3 Demographic Reach and Achievements
10.10.4 Mergers and Acquisitions
10.10.5 Certifications
10.11 Human Stem Cells Institute
10.11.1 Company Overview
10.11.2 Product Portfolio
10.11.3 Demographic Reach and Achievements
10.11.4 Mergers and Acquisitions
10.11.5 C ertifications
10.12 Kolon Tissuegene Inc.
10.12.1 Company Overview
10.12.2 Product Portfolio
10.12.3 Demographic Reach and Achievements
10.12.4 Mergers and Acquisitions
10.12.5 Certifications
10.13 Organogenesis Holdings Inc.
10.13.1 Company Overview
10.13.2 Product Portfolio
10.13.3 Demographic Reach and Achievements
10.13.4 Mergers and Acquisitions
10.13.5 Certifications
10.14 Renova Therapeutics
10.14.1 Company Overview
10.14.2 Product Portfolio
10.14.3 Demographic Reach and Achievements
10.14.4 Mergers and Acquisitions
10.14.5 Certifications
11 Recommendations and Discussion
12 Global Cell and Gene Therapy Market Distribution Model (Additional Insight)
12.1 Overview
12.2 Potential Distributors
12.3 Key Parameters for Distribution Partner Assessment
13 Payment Methods (Additional Insight)
13.1 Government Funded
13.2 Private Insurance
13.3 Out-of-Pocket
Key Questions Answered in the Report
The market is rising at a CAGR of 19.02% during 2023-2031.
The different types of cell therapy are Tumour-Infiltrating Lymphocyte therapy, Engineered T Cell Receptor therapy, Chimeric Antigen Receptor T cell therapy, and Natural Killer cell therapy.
The regions involved in the market are North America, Middle East and Africa, Latin America, Asia Pacific, and Europe.
The key companies involved in this market are Amgen Inc., Bluebird Bio, Inc., Castle Creek Pharmaceutical Holdings, Kite Pharma, Inc., Novartis AG, Orchard Therapeutics plc., Pfizer, Inc., Spark Therapeutics, Inc., Vericel Corporation, Dendreon Pharmaceuticals LLC., Human Stem Cells Institute, Kolon Tissuegene Inc., Organogenesis Holdings Inc., and Renova Therapeutics.
Cell and gene therapies involve the extraction of protein, genetic material, cells or genes from a patient, altering them as per the therapy, and then reinjecting them back into the patient.
Cell therapy works on the principle of alteration, implantation, or restoration of cells or by extrapolating cells to carry the treatment through the body. In contrast, gene therapy works by incorporating, deactivating, or displacing the genes into cells which can occur both inside (in vivo) and outside (ex vivo) of the body.
The three types of gene therapy are: in vivo, ex vivo, and in situ.
Cell and gene therapy treats a wide range of diseases. It is also used as a drug delivery system.
The risks associated with cell and gene therapy include inflammation and toxicity.
The cell and gene therapy incorporate cell and gene alteration; thus, these mutations can be a risk for future generations.
Genes are present within the cells, whereas cells are the basic building blocks of all living matter.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$3499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$5999-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$7999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$9999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
NEWSLETTER